News >

Atezolizumab Plus Carboplatin/Nab-Paclitaxel Improves OS in Frontline NSCLC

Jason M. Broderick @jasoncology
Published: Tuesday, May 29, 2018

Dr. Sandra Horning

Sandra Horning, MD
Adding atezolizumab (Tecentriq) to nab-paclitaxel (Abraxane) and carboplatin in the frontline setting significantly improved overall survival (OS) in patients with advanced non–small cell lung cancer (NSCLC), according to findings from the phase III IMpower130 study.

In data scheduled to be presented at the 2018 ASCO Annual Meeting, the atezolizumab combination also improved overall survival in the IMpower150 trial. In the ITT-WT population, the median OS was 19.2 months with atezolizumab compared with 14.7 months for patients receiving  bevacizumab and chemotherapy alone (HR, 0.78; 95% CI, 0.64-0.96; P = .016). 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x